Andrew James Moller - 02 Mar 2026 Form 4 Insider Report for CONMED Corp (CNMD)

Reporting relationship: VP Corporate Controller
Issuer ticker: CNMD
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 15:50:29 UTC
Prior SEC filing: 30 Jan 2025
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas Fistek for Andrew James Moller by Power of Attorney

Filing notes and source

Key filing fact

Andrew James Moller filed Form 4 for CONMED Corp (CNMD) on 04 Mar 2026.

Key facts

This page summarizes Andrew James Moller's Form 4 filing for CONMED Corp (CNMD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2026, 15:50.

Change

Previous filing in this sequence was filed on 30 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002054340 Primary reporting owner

Moller Andrew James

Relationship: VP Corporate Controller
Address: C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO
Signature: /s/ Thomas Fistek for Andrew James Moller by Power of Attorney
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNMD transaction Derivative

RSUs (Restricted Stock Units)

Award

Transaction value
Shares: +5,896
Change %
Price: $0.000000^*
Shares after: 5,896
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,896
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.